Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending May 31,
2018
BIOASIS TECHNOLOGIES INC . (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company developing its xB3
TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of
CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it
has filed its unaudited quarterly financial statements and management’s discussion and analysis for the period ended May 31,
2018. All are available under the Company's profile on SEDAR at www.sedar.com and on the Company's website at www.bioasis.us/investors/.
On behalf of the Board of Directors of Bioasis Technologies Inc.
Mark Day, Ph.D., Director and President & Chief Executive Officer
About Bioasis
Bioasis Technologies, Inc. is a biopharmaceutical company developing the xB3 TM platform, a proprietary technology
for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet
medical need, including brain cancers and neurodegenerative diseases. The delivery of therapeutics across the BBB represents the
final frontier in treating neurological disorders. The in-house development programs at Bioasis are designed to develop symptomatic
and disease-modifying treatments for brain-related diseases and disorders. The company maintains headquarters in Richmond, Canada
with offices in Guilford, Conn., United States. Bioasis trades on the TSX Venture Exchange under the symbol “BTI” and on the OTCQB
under the symbol “BIOAF.” For more information about the company, please visit www.bioasis.us.
“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.”
Media & Investor Relations:
Bioasis Technologies, Inc.
Catherine London, +1 917-763-2709
Catherine@bioasis.us
View source version on businesswire.com: https://www.businesswire.com/news/home/20180730005804/en/